Infant Bacterial Therapeutics AB (publ) (IBT-B) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Infant Bacterial Therapeutics AB (publ) stock SEK 38.88, price SEK 67.50, that is 42.4% below the price, quality 62 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Infant Bacterial Therapeutics AB (publ)
IBT-B · STFar too expensive (fair value 42% below the price), but solid company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range kr 31.60 – kr 124.50 · fair‑value band kr 29.16 – kr 48.59 · the kr 67.50 price screens above the kr 38.88 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Infant Bacterial Therapeutics AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden.
Show moreShow less
The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants.
It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.
In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections.
The company was incorporated in 2011 and is headquartered in Stockholm, Sweden.
Stock analysis
Infant Bacterial Therapeutics AB (publ) (IBT-B) currently trades at kr 67.50, while our estimate is kr 38.88, 42% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: kr 29.16 (bear) to kr 48.59 (bull), the price of kr 67.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Infant Bacterial Therapeutics AB (publ) reported revenue of 0 SEK in FY2025 versus 0 SEK in FY2021. Reported net income was −65.2M SEK in FY2025.
Key figures
Market cap 909M SEK (≈ $90.0M) Micro · EPS (TTM) kr −6.05 · Return on equity −87.4% · Return on assets (EBIT) −33.8% (5-year average) · Revenue (TTM) −1.0K SEK · Revenue growth (YoY) −61.5% · EPS growth (YoY) −61.7% · Free cash flow −72.3M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 55% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −42%, IBT-B screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Infant Bacterial Therapeutics AB (publ) with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/S ratio by industry
- EBIT margin by industry
- Stock screener with 62 metrics
- Valuation of the Sweden market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs IBT-B |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs IBT-B |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs IBT-B |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs IBT-B |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs IBT-B |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs IBT-B |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs IBT-B |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs IBT-B |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs IBT-B |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs IBT-B |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Infant Bacterial Therapeutics AB (publ) (IBT-B) overvalued or undervalued?
What is the fair value of IBT-B?
What is the quality score of IBT-B?
What is the price target for Infant Bacterial Therapeutics AB (publ) (IBT-B)?
What is the Infant Bacterial Therapeutics AB (publ) stock forecast for 2026?
What is the intrinsic value of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
Is Infant Bacterial Therapeutics AB (publ) stock overvalued or undervalued in 2026?
Is fair value the same as the market price of IBT-B?
How much is Infant Bacterial Therapeutics AB (publ) worth?
What do the bullish and bearish scenarios say about IBT-B?
How solid is the balance sheet of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
How far is IBT-B from its 52-week high?
Which stocks are comparable to Infant Bacterial Therapeutics AB (publ)?
Is Infant Bacterial Therapeutics AB (publ) stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
What should I pay attention to with Infant Bacterial Therapeutics AB (publ) right now?
Key figures of Infant Bacterial Therapeutics AB (publ)
How large is the market capitalisation of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
What are the earnings per share of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
What is the return on equity of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
What is the EBIT return on assets of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
How much revenue does Infant Bacterial Therapeutics AB (publ) (IBT-B) generate?
How fast is revenue growing at Infant Bacterial Therapeutics AB (publ) (IBT-B)?
How fast are earnings growing at Infant Bacterial Therapeutics AB (publ) (IBT-B)?
How much free cash flow does Infant Bacterial Therapeutics AB (publ) (IBT-B) generate?
How much net cash does Infant Bacterial Therapeutics AB (publ) (IBT-B) hold?
Watch Infant Bacterial Therapeutics AB (publ) in the live analysis
One click puts Infant Bacterial Therapeutics AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.